MedTrace Logo

Thailand HDV Cohort

NCT05350865 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 3152

Last updated 2024-10-02

No results posted yet for this study

Summary

There is very limited data of HDV in Thailand. As both HDV and HIV can accelerate the HBV course and increased the risk of death, particularly, among those with low CD4 cells/count, therefore, HDV burden in this special population is unmet need. Therefore, this study plans to perform a nationwide survey of the prevalence and predictor of HDV among people uses drugs (PWID) with and without HIV, HBV/HIV (MSM vs non MSM), HBV related cirrhosis. Findinds from this study will provide the scientific community to understand how important HDV is among HBV patients, this could be used to develop strategies for HDV screening and treatment

Conditions

  • HDV

Sponsors & Collaborators

  • King Chulalongkorn Memorial Hospital

    collaborator OTHER

  • Thai Red Cross AIDS Research Centre

    collaborator OTHER

  • Siriraj Hospital

    collaborator OTHER

  • Taksin Hospital

    collaborator UNKNOWN

  • Gilead Sciences

    collaborator INDUSTRY

  • The HIV Netherlands Australia Thailand Research Collaboration

    lead OTHER

Principal Investigators

  • Anchalee Avihingsanon, MD, PhD · HIV-NAT, Thai Red Cross - AIDS Research Centre

  • Pisit Tangkijvanich, MD · Biochemistry, Faculty of Medicine, Chulalongkorn University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-30
Primary Completion
2025-05-31
Completion
2025-05-31

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05350865 on ClinicalTrials.gov